Publicaciones (409) Publicaciones de SANTIAGO MORENO GUILLÉN

2024

  1. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

  2. COVID-19: On the threshold of the fifth year. The situation in Spain

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 37, Núm. 1, pp. 17-28

  3. Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration

    The Lancet HIV

  4. Decalogue to promote the implementation and improvement of recommendations for the early diagnosis of HIV in Emergency Departments

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 42, Núm. 5, pp. 267-271

  5. Effectiveness and Safety of Direct-acting Antivirals for Treatment of Adolescents With HCV/HIV Coinfection: Real-world Data From Europe

    Pediatric Infectious Disease Journal, Vol. 43, Núm. 5, pp. E155-E159

  6. Feasibility of a selective targeted strategy of HIV testing in emergency departments: a before-after study

    European Journal of Emergency Medicine, Vol. 31, Núm. 1, pp. 29-38

  7. Meningococcal meningitis in Spain in the Horizon 2030: A position paper

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 37, Núm. 4, pp. 285-298

  8. Respiratory syncytial virus: A new era

    Revista Espanola de Quimioterapia, Vol. 37, Núm. 2, pp. 134-148

  9. Transition times across the HIV care continuum in Spain from 2005 to 2022: a longitudinal cohort study

    The Lancet HIV, Vol. 11, Núm. 7, pp. e470-e478

2023

  1. A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease

    Frontiers in Immunology, Vol. 14

  2. Advantages and disadvantages of maintaining the mandatory use of masks in health centers and nursing homes in Spain. How and when is it justified to maintain it?

    Revista Espanola de Quimioterapia, Vol. 36, Núm. 5, pp. 466-469

  3. CD4/CD8 Ratio During Human Immunodeficiency Virus Treatment: Time for Routine Monitoring?

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 76, Núm. 9, pp. 1688-1696

  4. Comparison of the Fecal Bacteriome of HIV-Positive and HIV-Negative Older Adults

    Biomedicines, Vol. 11, Núm. 8

  5. Expanding HIV clinical monitoring: the role of CD4, CD8, and CD4/CD8 ratio in predicting non-AIDS events

    EBioMedicine, Vol. 95, pp. 104773

  6. Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2

    Viruses, Vol. 15, Núm. 7

  7. Insights for COVID-19 in 2023

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 36, Núm. 2, pp. 114-124

  8. Sexually transmitted infections in Spain: Current status

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 36, Núm. 5, pp. 444-465

  9. Status of Herpes Zoster and Herpes Zoster Vaccines in 2023: A position paper

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 36, Núm. 3, pp. 223-235

  10. Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B

    Digestive Diseases and Sciences, Vol. 68, Núm. 6, pp. 2731-2737

  11. Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 76, Núm. 3, pp. e116-e125